Minerva Neurosciences, Inc. NERV
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a CNS/neurology/psychiatry drug developer. Its lead program, roluperidone, is in Phase 3 for negative symptoms of schizophrenia. Its next catalyst on record is roluperidone: C19 Phase 3 topline efficacy results (12-week primary endpoint) (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: roluperidone — C19 Phase 3 topline efficacy results (12-week primary endpoint) (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| roluperidone (C19 confirmatory trial) | negative symptoms of schizophrenia | small molecule | Phase 3 |
Recent results and decisions
- May 5, 2026started Confirmatory Phase 3 roluperidone trial initiated and first patient screened in March 2026.
The Company screened the first patient in March 2026, marking an important operational milestone for the program.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.